Quarterly ResultMay 5, 2026, 04:14 PM
Vertex Q1 Net Income +60% to $1.03B; Revenue $2.99B
AI Summary
Vertex Pharmaceuticals reported a significant increase in financial performance for the first quarter of 2026, with net income rising by 60% to $1.03 billion and total revenues reaching $2.99 billion. This strong growth was primarily driven by an 8.2% increase in product revenues and the absence of a $379.0 million intangible asset impairment charge that impacted the prior year's results. The company also generated $1.43 billion in net cash from operating activities and repurchased $344.5 million of common stock, with $3.0 billion remaining under its 2025 share repurchase program.
Key Highlights
- Net income increased by 59.6% to $1,031.4 million in Q1 2026 from $646.3 million in Q1 2025.
- Diluted EPS rose by 61.4% to $4.02 in Q1 2026, up from $2.49 in Q1 2025.
- Total revenues grew by 7.8% to $2,986.9 million in Q1 2026 from $2,770.2 million in Q1 2025.
- Product revenues, net, increased by 8.2% to $2,986.9 million in Q1 2026.
- Net cash provided by operating activities surged by 74.4% to $1,428.1 million.
- Repurchased $344.5 million of common stock in Q1 2026, with $3.0 billion remaining in the program.
- No intangible asset impairment charge in Q1 2026, compared to $379.0 million in Q1 2025.